Our approach

We follow the biology to the indication

Most development programs start with a disease and go looking for a molecule. Azalla started with a chemical class, characterized what it actually does in a living immune system, and then let that answer choose the diseases. It is a slower way to pick a target and a much faster way to be right about it.

How we work

Six operating principles

These are not aspirations. Each one is visible in a decision we have already made, and we can show you the data behind it.

Evidence selects the indication, not the other way around

Our compounds were first characterized in a general, well-understood autoimmune inflammation model that asks a broad question rather than a convenient one. We then read the mechanistic and cytokine signature the molecules actually produced and let that signature nominate the diseases.

J-041 drove a large, highly significant reduction in CXCL10, an interferon-pathway chemokine central to dermatomyositis. That is what pointed the lead asset at dermatomyositis. J-019 carried confirmed PPARγ activity alongside CB2 agonism, a combination relevant to both inflammation and nerve tissue protection. That is what pointed it at multiple sclerosis. In both cases the indication came second.

One chemistry, carried deliberately across two programs

Both candidates come from a single proprietary chemical class. That is a design decision, not a coincidence. One synthetic route, one set of analytical methods, one formulation platform and one manufacturing base serve both programs, executed by the same partners under the same protocols.

Each compound still carries its own regulatory toxicology package — that work cannot be shared and we do not pretend otherwise. But the platform work underneath both is done once, which is what lets a company of our size run two candidates rather than one.

A small core, a deep external bench

Strategy, chemistry and program direction are held in house and are not delegated. Everything that a larger company would staff as a standing department — medicinal chemistry scale-up, in vivo pharmacology, formulation, DMPK, toxicology, regulatory counsel — runs through named specialist groups who have already done the work on these molecules.

The practical effect is that capacity scales with the program instead of the payroll, and the people doing each piece of work are the people who do that piece of work for a living.

Study designs that can change the plan

We do not run studies to confirm what we already believe. The pivotal in vivo study was designed against a potent corticosteroid rather than against vehicle alone — a materially harder comparison that a program optimizing for a clean slide would have avoided. Both compounds were run in the same study, in the same animals, so the cross-comparison is genuine. Scoring was done by an independent contract research organization, and the terminal readout was a broad multi-analyte cytokine panel rather than a single endpoint chosen after the fact.

Every gate is written down before the study starts, including what result would make us reorder the pipeline or stop.

Capital efficiency as a design constraint

Being lean is not a consequence of being small; it is how the program was engineered. The orphan-eligible asset leads because orphan development reaches the clinic on smaller trials and a shorter path. The second asset inherits a chemistry and CMC package it did not have to pay to build. Work is placed with groups who already have the assay, the model or the method validated.

The test we apply to every line of spend is simple: does this buy a data point that changes a decision?

Regulatory strategy chosen at the start, not retrofitted

The oral route, the immune-restricted target, the orphan pathway on the lead asset and the choice of active comparator were all settled before the enabling work began, with FDA regulatory counsel engaged from the outset. Composition-of-matter protection was filed on the chemical class rather than on a single molecule.

Deciding these things early is unglamorous, and it removes an entire category of late, expensive surprise.

In practice

What following the science actually looked like

The same program run with a predetermined disease target would have made different choices at each of these points.

Decision	The conventional route	What we did	Why it mattered
Choosing the first in vivo model	Model the target disease immediately	A general autoimmune model first, to characterize the chemistry honestly	Produced a mechanistic signature broad enough to nominate two indications instead of validating one assumption
Choosing the comparator	Vehicle control	An active corticosteroid, alongside vehicle	Turned the result into something a clinician and a reviewer can interpret rather than a relative improvement over nothing
Running two candidates	Separate studies, staged years apart	Both compounds in the same study, same arms, same scorer	Made the head-to-head comparison real and removed cross-study noise from the sequencing decision
Choosing the readout	A single primary endpoint	Clinical score, an independent functional endpoint, a broad multi-analyte cytokine panel and histopathology	Let the mechanism, not the headline, select the indication for each molecule
Choosing the lead	Lead with the larger market	Lead with the orphan indication the data pointed to	Shorter regulatory path, smaller trials and a second asset that follows on the same platform

Source: In vivo efficacy and cell-based receptor pharmacology studies conducted by independent contract research organizations.

Operating model

Built to move, not to staff up

Held in house

Corporate and program strategy, and the sequencing decisions between the two assets.
Medicinal chemistry direction and the design of the chemical class.
Regulatory strategy, intellectual property strategy and study design.
Which questions get asked next, and what answer would change the plan.

Run through named specialists

An integrated discovery organization — an embedded development team covering chemistry, DMPK, in vivo pharmacology and formulation.
A specialist in vivo CRO — efficacy studies, independent scoring and mechanism-of-action work.
A receptor pharmacology provider — CB2 and PPARγ assay panels.
A disease-model specialist — additional autoimmune models.
Dedicated patent and FDA regulatory counsel — prosecution and orphan/IND strategy.

The people behind the programs

Boundaries

What we are not doing

Not building a discovery platform in search of a disease. Two candidates, two named indications, defined gates.
Not pursuing a broad anti-inflammatory label. CB2 is immune-restricted, and the selectivity margin over CB1 on the lead is the point of the chemistry, not a footnote to it.
Not a cannabis or consumer wellness company. These are single-molecule, synthetically manufactured oral pharmaceuticals developed under the same regulatory standard as any other small molecule.
Not claiming clinical benefit. Both compounds are preclinical and investigational, and nothing observed in an animal model is a statement about people.

Talk to us about the programs

Scientific, partnering, clinical, media and corporate inquiries all come through one form and are read by the people running the program.